Details for New Drug Application (NDA): 202602
✉ Email this page to a colleague
NDA 202602 describes EXEMESTANE, which is a drug marketed by Alvogen, Amneal Pharms, Breckenridge, Cipla, Dr Reddys Labs Sa, Eugia Pharma, Hikma, Qilu, Rising, Upsher Smith Labs, and Zydus Pharms, and is included in eleven NDAs. It is available from eleven suppliers. Additional details are available on the EXEMESTANE profile page.
The generic ingredient in EXEMESTANE is exemestane. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the exemestane profile page.
The generic ingredient in EXEMESTANE is exemestane. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the exemestane profile page.
Summary for 202602
| Tradename: | EXEMESTANE |
| Applicant: | Zydus Pharms |
| Ingredient: | exemestane |
| Patents: | 0 |
Pharmacology for NDA: 202602
| Mechanism of Action | Aromatase Inhibitors |
Suppliers and Packaging for NDA: 202602
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EXEMESTANE | exemestane | TABLET;ORAL | 202602 | ANDA | Zydus Pharmaceuticals USA Inc. | 68382-383 | 68382-383-06 | 30 TABLET in 1 BOTTLE (68382-383-06) |
| EXEMESTANE | exemestane | TABLET;ORAL | 202602 | ANDA | Zydus Lifesciences Limited | 70771-1374 | 70771-1374-3 | 30 TABLET in 1 BOTTLE (70771-1374-3) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Oct 3, 2018 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
